# Pilot Study of Hemoglobin Based Oxygen Therapeutics in Elective Coronary Revascularization

> **NCT00317512** · PHASE2 · COMPLETED · sponsor: **Biopure Corporation** · enrollment: 45 (actual)

## Conditions studied

- Angina Pectoris
- Unstable Angina
- Myocardial Infarction

## Interventions

- **PROCEDURE:** Percutaneous Coronary Revascularization
- **DRUG:** Hemoglobin-Based Oxygen Carrier-201 (HBOC-201)
- **DRUG:** Voluven

## Key facts

- **NCT ID:** NCT00317512
- **Lead sponsor:** Biopure Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2005-04
- **Final completion:** 2007-07
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2008-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00317512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00317512, "Pilot Study of Hemoglobin Based Oxygen Therapeutics in Elective Coronary Revascularization". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00317512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*